Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NFrnU4pHfW6ldHnvckBCe3OjeR?= MnLZNE4yNTNyIN88US=> NWXMOFN6PDhiaB?= Mlv5bY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> M4jlRVI3PTF|MUey
H460 M1jEUWZ2dmO2aX;uJGF{e2G7 M17S[lAvOS1|MDFOwG0> M4ryb|Q5KGh? MnrNbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> NWTWXXV7OjZ3MUOxO|I>
HKESC-2 NW\kVJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4frUVIxyqEQvF2= NXPNO2d7PDkEoHlCpC=> MmjDd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh NYHNZVQyOjZ2N{S2PVM>
CaES-17 NWT3TnhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TkWlIxyqEQvF2= MX:0POKhcMLi M4mxcZNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? NInmbWszPjR5NE[5Ny=>
HKESC-2 M2ftV2Fxd3C2b4Ppd{BCe3OjeR?= NYXYR3R2OjEEoN88US=> MoDDOFjDqGkEoB?= M1q5O5Jm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NGfHU5YzPjR5NE[5Ny=>
CaES-17 M2jibWFxd3C2b4Ppd{BCe3OjeR?= NXyxVlJSOjEEoN88US=> NHjMblA1QMLiaNMg M{XIeZJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MlTRNlY1PzR4OUO=
A549 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknsOU0yPjBizszN NWizTI5VPDkEoHlCpC=> MXrEUXNQ M1i3VGlEPTB;MU[zMlQh|ryP MVGyOlQ3PDZ2Mx?=
HCC827 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XMWlUuOTZyIN88US=> M{nUTFQ5yqCqwrC= M4jqRmROW09? NXHXXYFFUUN3ME22PU4zKM7:TR?= MnPYNlY1PjR4NEO=
A549 NWDhbHk6SXCxcITvd4l{KEG|c3H5 Mm\LPFAhyrWP NWn4VZhXPDkEoHlCpC=> MVXEUXNQ M{TldIlv\HWlZYOgZZBweHSxc3nz NUf3XFhyOjZ2NkS2OFM>
HCC827 MmG2RZBweHSxc3nzJGF{e2G7 MnPRPFAhyrWP MVm0POKhcMLi MX\EUXNQ NIq4cWVqdmS3Y3XzJIFxd3C2b4Ppdy=> NHXLWWczPjR4NE[0Ny=>
SGC-7901/DDP NIHKXYlHfW6ldHnvckBCe3OjeR?= M3vGRlExyqEEtV2= M1;Y[lI1KGh? MlrLbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW|c3nvci=> NFnM[lIzPjRyN{[1Ny=>
SGC-7901  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf2NlTDqGkEoB?= NUjBe5lCUUN3ME2xNVUvODhizszN MViyOlQxPzZ3Mx?=
SGC-7901/DDP NYq2VoV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K1SlI1yqCqwrC= MYPJR|UxRTN3LkS1JO69VQ>? MXeyOlQxPzZ3Mx?=
SGC-7901/DDP MkjHRZBweHSxc3nzJGF{e2G7 M4rP[FExyqEEtV2= MkH5NlQhcA>? MYLpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKHerdHigZ4l{eGyjdHnu NF34dowzPjRyN{[1Ny=>
SGC-7901/DDP MWLGeY5kfGmxbjDBd5NigQ>? MXexNOKhyrWP NWS1bYVpOjRiaB?= NHfRNopqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?= Mo\sNlY1ODd4NUO=
SGC-7901/DDP MXXGeY5kfGmxbjDBd5NigQ>? M3nkN|ExyqEEtV2= NEDBW4UzPCCq MVPjZZV{\XNiYTDtZZJs\WRiZHXjdoVie2ViaX6geIhmKGyndnXsJI9nKEKlbD2yJJBzd3SnaX6= MVWyOlQxPzZ3Mx?=
H357 M2SzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vKeVcvPS9zMDFOwG0> NF3nfGk1QCCq MkTmSG1UVw>? NYD6cmx4cW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>? MnTNNlYxODl6N{S=
TAF Mom3SpVv[3Srb36gRZN{[Xl? M4nyNFExyqEEtV2= MXW3JIQ> NFnHUYZi\m[nY4TzJHRCTnNiYXTo[ZNqfmVicILvdIVzfGmncx?= M2fHOlI2QTh5MUK3
TAF MUHGeY5kfGmxbjDBd5NigQ>? M3;SW|ExyqEEtV2= MVSzNE0yOjBibXnu NI\xTldxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> NEDBZmYzPTl6N{GyOy=>
TAF MlzpSpVv[3Srb36gRZN{[Xl? MX6xNOKhyrWP NEDTfow1QCCq MWHpcoNz\WG|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M2O4XVI2QTh5MUK3
PANC-1 M1PTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvLNlAwPjBxMUCwJO69VQ>? NYLMVY5IOjRxNEivO|IhcA>? NUXYeopGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MVqyOVk4OzB4Mh?=
PANC-1 M2nUVWZ2dmO2aX;uJGF{e2G7 MYKyNE83OC9zMECg{txO MY[yOEBp NVzBTI9y[XS2ZX71ZZR{KGOnbHygbY53[XOrb36gZY5lKG2rZ4LheIlwdiCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MlLKNlU6PzNyNkK=
HeLa  M3fZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmyNOKh|ryPwrC= M1HpXFI1yqCq NY\EcWNx\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NIixc|UzPTd5MESyNy=>
SACC-83 NY\pUoFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjlb24zOMLizszNxsA> NYOxOWlXOjUEoHi= NUL1U5BU\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= MUeyOVc4ODR{Mx?=
HeLa  MYHBdI9xfG:|aYOgRZN{[Xl? MVyyNOKh|ryPwrC= MV[yOOKhcA>? M1m4boVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> MmDJNlU4PzB2MkO=
SACC-83 MkTrRZBweHSxc3nzJGF{e2G7 MnjwNlDDqM7:TdMg NV;SfmNoOjUEoHi= NV20TWlb\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? MWKyOVc4ODR{Mx?=
HeLa  NVLqOIVuTnWwY4Tpc44hSXO|YYm= M1:4d|IxNzRyL{iwJO69VQ>? NVjPc2RoOjUEoHi= MorDeZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> NUfmUmlDOjV5N{C0NlM>
SACC-83 M{\lS2Z2dmO2aX;uJGF{e2G7 MkjONlAwPDBxOECg{txO NVTLU2FSOjUEoHi= NH;vPId2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? NHTYWHAzPTd5MESyNy=>
HLCZ01 NGXkXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDoOVEx6oDVNkFCpOK2VQ>? NGPCc|I1QCCq NX7W[5hiTE2VTx?= Moe3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NX\3VZV7OjV5MkS4PVk>
HLCZ01 M{DkRmZ2dmO2aX;uJGF{e2G7 NXqxUJFVPDEEoN88US=> NX20OpI5OjRiaB?= NECzUHdFVVOR M3HaZ4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NHvRO|AzPTd{NEi5PS=>
HLCZ01 M4HuXmFxd3C2b4Ppd{BCe3OjeR?= MXi0NOKh|ryP M1n1eVI1KGh? MoDpSG1UVw>? Mofa[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y MlnUNlU4OjR6OUm=
HLCZ01 MoG2SpVv[3Srb36gRZN{[Xl? NGroOWE1OMLizszN Mn7HNlQhcA>? MlnsSG1UVw>? MkWwbY5kemWjc3XzJHRTSUmOIHX4dJJme3Orb36gZ49u[mmwZXSge4l1cCCLboTldoZmem:wLd8x M13KWFI2PzJ2OEm5
MGC803 M3Oyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnjNE03OCEQvF2= NUTQ[VcyPzJiaB?= MXfJR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= NV7adIJsOjV5MEGzO|g>
SGC7901 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi0c3kxNTZyIN88US=> NU\RS2piPzJiaB?= Mk\LTWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2= MY[yOVcxOTN5OB?=
MGC803 NXnCTIp3TnWwY4Tpc44hSXO|YYm= MUK0NOKh|ryP MWq4M|E3NzJ2IHi= MWH1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= MlfFNlU4ODF|N{i=
SGC7901 M1TGVmZ2dmO2aX;uJGF{e2G7 MlzCOFDDqM7:TR?= MX24M|E3NzJ2IHi= M3LNTZVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NWfacVZmOjV5MEGzO|g>
MCF-7  M{LhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\1NU8yOCEQvF2= M4PDeFczKGh? MWjEUXNQ M4DSfIVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w M2\Z[FI2PjZ5NUGw
MDA-MB-231  MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHJWGNPOS9zMDFOwG0> NX3kOoczPzJiaB?= NGXlNHBFVVOR M2nqZ4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MlrZNlU3Pjd3MUC=
MDA-MB-231 MXrGeY5kfGmxbjDBd5NigQ>? NXu5fHByOC12MDFCuW0> MkfVOE0zPCCq Ml3PbY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MnzGNlU2QDd|Mkm=
MCF-7 NV7TS3FlTnWwY4Tpc44hSXO|YYm= M2rXVlAuPDBiwsXN M1;KblQuOjRiaB?= NVq5cVU1\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= NHvhTHAzPTV6N{OyPS=>
MCF7-MX  NG\ZSJBHfW6ldHnvckBCe3OjeR?= M{W1dVAuPDBiwsXN NFrqb2w1NTJ2IHi= NGC5VGRmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi NXHtc|lbOjV3OEezNlk>
MDA-MB-231 NFTQS|dHfW6ldHnvckBCe3OjeR?= M{TqVFAuPDBiwsXN NWK5d45wPC1{NDDo MYPzeIlufWyjdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGFDS0d{IIXwJJRwKDRwMkegeIlu\XNidH:gZ49vfHKxbDDs[ZZmdCCkeTCxNkBpyqB? M4Hw[VI2PTh5M{K5
A2780 NXWyXJJkTnWwY4Tpc44hSXO|YYm= MoGyOU8yOC9zNTFOwG0> M2TxdFQ5KGh? NHzVN2Vl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MViyOVQzPDh7OB?=
SKOV3  Mkf6SpVv[3Srb36gRZN{[Xl? NEHJT5M2NzFyL{G1JO69VQ>? M1jqSlQ5KGh? NIDPRmpl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkGxNlU1OjR6OUi=
A2780 NYXZOVJLTnWwY4Tpc44hSXO|YYm= NH\HUXo2NzFyL{G1JO69VQ>? NHzKUWQ1QCCq NWe2TYFP\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= MVmyOVQzPDh7OB?=
SKOV3  NFLwfXZHfW6ldHnvckBCe3OjeR?= MofpOU8yOC9zNTFOwG0> M1fB[|Q5KGh? NIP1d3RmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw Ml36NlU1OjR6OUi=
A2780 M13UUWZ2dmO2aX;uJGF{e2G7 NHTqUZg2NzFyL{G1JO69VQ>? MVW0PEBp M3uwUIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= MXSyOVQzPDh7OB?=
SKOV3  M12yXWZ2dmO2aX;uJGF{e2G7 Ml;HOU8yOC9zNTFOwG0> M3rW[|Q5KGh? MYDk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? MmX6NlU1OjR6OUi=
A2780 NV3DbJI{TnWwY4Tpc44hSXO|YYm= NULQe4Y4PS9zMD:xOUDPxE1? MmqyNUBp MoPTbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVPUOHZtOjV2MkS4PVg>
SKOV3  Ml\1SpVv[3Srb36gRZN{[Xl? NHPvT3E2NzFyL{G1JO69VQ>? M1PCUVEhcA>? NH7JUmRqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2rR[VI2PDJ2OEm4
HCT-15 MVrGeY5kfGmxbjDBd5NigQ>? MYOxNE02OCEQvF2= NIO5cVA3NTN4IHi= NYj4R5o4cW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MVqyOVIyQDB{OB?=
HT-29  NFjGeZVHfW6ldHnvckBCe3OjeR?= MnzONVAuPTBizszN NUDTb3RVPi1|NjDo M3rQ[Ylv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MV6yOVIyQDB{OB?=
HSC3  M{jXXGNmdGxiVnnhZoltcXS7IFHzd4F6 NVvzUI9xOOLCk{SwJO69VQ>? MXS0PEBp MYfJR|UxRTJ3LkZCtVEvPzhyIN88US=> NWTRXllCOjVzOUi3PFk>
HSC3  M2\PRmFxd3C2b4Ppd{BCe3OjeR?= NGqxV3AzPSEQvF2= M1vSdFQ5KGh? NFyySZVqdmS3Y3XzJIFxd3C2b4Ppdy=> M1jDW|I2OTl6N{i5
HSC3  MYLGeY5kfGmxbjDBd5NigQ>? NUnHOVZwOjVizszN MmGwOFghcA>? MUnlfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV NHn6NIYzPTF7OEe4PS=>
HSC3  M4[wT2Z2dmO2aX;uJGF{e2G7 NIjle2ozPSEQvF2= M1fld|Q5KGh? NFHybZVqdmirYnn0d{BJW0N|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ> MUmyOVE6QDd6OR?=
HSC3  NGDteFNHfW6ldHnvckBCe3OjeR?= MlG0NlUh|ryP MXG3NkBp M{[0VYRm[3KnYYPld{BOVVBvMjDhcoQhVU2SLUmgdJJwfGWrboRCpC=> NGDHXo8zPTF7OEe4PS=>
201T  NWn1U2lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXkO|IhcA>? MYDEUXNQ MorOTWM2OD12OD62JOK2VQ>? MWiyOVA2Pzl2MR?=
273T M{PzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[3NkBp NV;VcZBvTE2VTx?= MkCxTWM2OD16MD61JOK2VQ>? MmP6NlUxPTd7NEG=
Hep-2 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G0OlMxNzVyL{GwNEDPxE1? MoXWNVIwOjRxM{[vOFghcA>? M3jaUWROW09? MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUSyOFk6QDV4NB?=
Hep-2 Mn24RZBweHSxc3nzJGF{e2G7 NHXt[4M2OCEQvF2= MXewMVQ5KGh? Ml31SG1UVw>? NV;NeYVCcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NGrJRlIzPDl7OEW2OC=>
Hep-2 Mm\LSpVv[3Srb36gRZN{[Xl? Ml\ZOVAh|ryP MmjHNE01QCCq NFi1fnhFVVOR NF74eGhz\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?= MoPTNlQ6QTh3NkS=
Hep-2 NXS3TZh5TnWwY4Tpc44hSXO|YYm= MnPUOVAh|ryP MV6wMVQ5KGh? M4TLd2ROW09? NWi5R|BU\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? M3z4NVI1QTl6NU[0
SGC-7901 NFHxVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP4NVAwPTBxMUCwJO69VQ>? NILYRWwzPC92OD:3NkBp NGW1XoNFVVOR NEjlOZFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{DnV|I1QTl{OUW4
MKN-45 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDENVAwPTBxMUCwJO69VQ>? NXX1S4w2OjRxNEivO|IhcA>? Mn[xSG1UVw>? MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NVnEe|ljOjR7OUK5OVg>
SGC-7901 MlvvSpVv[3Srb36gRZN{[Xl? NFP6eJQyOC93MD:xNFAh|ryP MkjxOFghcA>? MkTxSG1UVw>? NWrzXW1k\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mmj1NlQ6QTJ7NUi=
MKN-45 MmLDSpVv[3Srb36gRZN{[Xl? NIjsVJAyOC93MD:xNFAh|ryP M{fMclQ5KGh? MVLEUXNQ NILvZ4hld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MoTiNlQ6QTJ7NUi=
C666-1 M4X2XGN6fG:2b4jpZ4l1gSCDc4PhfS=> M334XFIxNThyIN88US=> NGroeoMzPCCq NVi0VY5v\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MoLwNlQ5PTR6M{i=
CNE-1 NWP0TJdGS3m2b4TvfIlkcXS7IFHzd4F6 NHLDOYEzOC16MDFOwG0> MYSyOEBp MoTM[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> MWqyOFg2PDh|OB?=
CNE-2 MmDNR5l1d3SxeHnjbZR6KEG|c3H5 NFnUWHMzOC16MDFOwG0> M1jnZVI1KGh? Ml:0[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> M3nuOFI1QDV2OEO4
C666-1 Ml;vR5l1d3SxeHnjbZR6KEG|c3H5 MY[2NEDPxE1? NHLrTpI4KGR? MYDlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= MUeyOFg2PDh|OB?=
CNE-1 NH;ZT49EgXSxdH;4bYNqfHliQYPzZZk> M1K4XVYxKM7:TR?= NGjJeXY4KGR? Mmja[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= M3Lr[VI1QDV2OEO4
SNU-1041 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHPOWRKOC12MDFOwG0> M1fSRVQ5KGh? NFfrOmpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MXuyOFY6OjdyMx?=
SNU-1041 NYrWSpJkTnWwY4Tpc44hSXO|YYm= NHHFU|AzOC9|MDFOwG0> NFrxSWY1KGh? M4Hn[Ilv\HWlZYOg[ZhxemW|c3nvckBw\sLiQ1jPVEwhT1KSN{lCpIFv\MLiWFLQNeKh[XRidHjlJHJPSSCuZY\lcOKh MnPSNlQ3QTJ5MEO=
SNU-1041 NGTVN2pHfW6ldHnvckBCe3OjeR?= MUCwMVQxKM7:TR?= NFvofJE1KGh? MXL1dE1z\We3bHH0[ZMhS0iRUNMgZYZ1\XJidILlZZRu\W62IIfpeIghcGmpaDDjc45k\W62cnH0bY9vew>? M3uzXlI1Pjl{N{Cz
SGC-7901 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi1NE0yOjVizszN MnnkNlQwPDhxN{KgbC=> NV7UWZE6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NIXreJMzPDZ5NkO5OC=>
SGC-7901 NVTLOYw3SXCxcITvd4l{KEG|c3H5 M4XOcVExOCEQvF2= NHr5VoU4OiCq NHrUeW9qdmS3Y3XzJIFxd3C2b4Ppdy=> NWC0OGtyOjR4N{[zPVQ>
SGC-7901 NEKwZoRHfW6ldHnvckBCe3OjeR?= MkfGO|UwOTByL{GyOUDPxE1? NVvHUlI2OjRxNEivO|IhcA>? NVLRZZJ1cW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> NIPGTZgzPDZ5NkO5OC=>
LMeC  MXjGeY5kfGmxbjDBd5NigQ>? NGrR[2EzOC93MDFOwG0> MoHrOFghcA>? NWTnW5M5\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEORWD2yJJBzd3SnaX6= NXHo[JlOOjR4NU[3OFY>
CMeC-1 MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlXwNlAwPTBizszN NWntOpVmPDhiaB?= NIL5OndqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkPUNlQ3PTZ5NE[=
LMeC MkjDR4VtdCCYaXHibYxqfHliQYPzZZk> NXm2UlhmOjBxNUCg{txO NE\CVmg1QCCq MVTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXqyOFY2Pjd2Nh?=
CMeC-1 MV;GeY5kfGmxbjDBd5NigQ>? NFTMTmgzOC93MDFOwG0> NGi3OmI1QCCq NIrNZ5BqdmS3Y3XzJGcyNVNiYYLy[ZN1 MV6yOFY2Pjd2Nh?=
LMeC MXvGeY5kfGmxbjDBd5NigQ>? MnrJNlAwPTBizszN MkjPOFghcA>? M2ntTIlv\HWlZYOgS|EuWyCjcoLld5Q> M2[xdlI1PjV4N{S2
CMeC-1 M2CzV2Z2dmO2aX;uJGF{e2G7 MXiyNE82OCEQvF2= MUm0PEBp MUPk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4DzV|I1PjV4N{S2
LMeC NW\TO2plTnWwY4Tpc44hSXO|YYm= MnPFNlAwPTBizszN NWWxTY5RPDhiaB?= Mnyy[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGTMOIUzPDZ3Nke0Oi=>
CMeC-1 MX\GeY5kfGmxbjDBd5NigQ>? NX:w[WN7OjBxNUCg{txO MmDhOFghcA>? MmLpbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MXKyOFY2Pjd2Nh?=
LMeC M{mwOWZ2dmO2aX;uJGF{e2G7 NH\pVW8zOC93MDFOwG0> MmPhOFghcA>? NGDtRm9qdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v M33DOFI1PjV4N{S2
OVCAR-3 MlrxR4VtdCCYaXHibYxqfHliQYPzZZk> NEnnUWkyOCEEtV2= NVHYXHhROSCq M4TZWIVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> M{TRUFI1PTJyMkK3
OVCAR-3 NWnuWHNqSXCxcITvd4l{KEG|c3H5 M4DNTVExKML3TR?= M3zoXVEhcA>? MlLydJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh MmrtNlQ2OjB{Mke=
OVCAR-3 NXLkblJWTnWwY4Tpc44hSXO|YYm= MUmxNEDDvU1? MXKxJIg> NWe1UoNV\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> NFexco0zPDV{MEKyOy=>
OVCAR-3 M33uO2Z2dmO2aX;uJGF{e2G7 NXnVTFM6OTBiwsXN M1LLclEhcA>? M1X4TIRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> MWKyOFUzODJ{Nx?=
OVCAR-3 NUS0ZldkTnWwY4Tpc44hSXO|YYm= MXqxNEDDvU1? NHjSbVQyKGh? MVHpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MVGyOFUzODJ{Nx?=
CF33 NXrCTHdTTnWwY4Tpc44hSXO|YYm= MmX1NVAxKM7:TR?= M{\vbVI1KGh? NEDIc3BqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= MUOyOFUxOzd6Mh?=
CF33 NFPLbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK0OlN4OTBvMUCwJO69VQ>? MoTxNE01KGR? NEjlU2lqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYfofWxxOjR3MEO3PFI>
CF33 NIHNc3hHfW6ldHnvckBCe3OjeR?= NEPvOYcyOC1zMECg{txO M{SySlQuOjRiaB?= NXHpc25k\GWlcnXhd4V{KGOnbHzzJIlvKHSqZTDTJJBp[XOnIHHu[EBqdmO{ZXHz[ZMh[2WubIOgbY4hTzBxR{GgZZJz\XO2 MWSyOFUxOzd6Mh?=
LNCaP M1\t[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f3ZVIwPS9zMDFOwG0> MWW5OkBp M3jlS4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= MXmyOFI6Pjl5OB?=
LNCaP Mlj5RZBweHSxc3nzJGF{e2G7 NUnMWHNIOi93L{GwJO69VQ>? NYqybHR{QTZiaB?= NX\DenVPcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG|dHH0bY4> NILx[2MzPDJ7Nkm3PC=>
PC-3  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XDeVAuPTBizszN Mn7pOFjjiImq NFiwTWhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2r2SlI1OTJ5OEiy
PC-3  MmnjR4VtdCCYaXHibYxqfHliQYPzZZk> MlrMNE0yODBizszN MoD6O|IhcA>? MVLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M{XsW|I1OTJ5OEiy

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID